- Home
- STDN vs NVCR Comparison
STDN vs NVCR Comparison
Compare STDN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STDN | NVCR |
|---|---|---|
| Founded | 2024 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | STDN | NVCR |
|---|---|---|
| Price | $11.56 | $13.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $17.25 | ★ $25.71 |
| AVG Volume (30 Days) | 265.4K | ★ 1.8M |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $439.23 | $12.91 |
| Revenue Next Year | $259.21 | $9.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $7.05 | $9.82 |
| 52 Week High | $17.34 | $21.45 |
Technical Indicators
Market Signals| Indicator | STDN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 35.14 |
| Support Level | $11.42 | $11.61 |
| Resistance Level | $13.73 | $18.43 |
| Average True Range (ATR) | 0.81 | 0.76 |
| MACD | -0.07 | -0.12 |
| Stochastic Oscillator | 10.06 | 32.87 |
Price Performance
Historical ComparisonAbout STDN Standard Nuclear Inc. Class A Common Stock
Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.